China National Medicines Corporation Ltd. China National Medicines Corporation Ltd.

China National Medicines Corporation Ltd.

600511

주식 순위 #4964
China National Medicines Corporation Ltd., in conjunction with its various... China National Medicines Corporation Ltd., in conjunction with its various operating entities, is a prominent player in the distribution of pharmaceutical goods across China. The enterprise's scope extends to the production and commercialization of innovative as well as pre-existing drug formulations. Additionally, it markets both traditional Chinese patent remedies and modern Western medications, alongside a range of medical apparatus. Complementing these activities, the firm delivers warehousing solutions and acts as an agent for import and export transactions. Its diverse clientele encompasses hospitals, retail pharmacies, and other healthcare organizations. Established in 1999, the company maintains its principal office in Beijing, China.
주가
$4.02
시가총액
$3.03B
변동 (1일)
3.01%
변동 (1년)
-0.69%
국가
CN
거래 China National Medicines Corporation Ltd. (600511)

카테고리

Healthcare
China National Medicines Corporation Ltd. (600511)의 매출
Jun 2026 기준 매출 TTM: $7.76B
China National Medicines Corporation Ltd.의 최신 재무 보고서에 따르면 회사의 현재 수익 (TTM)은 $7.76B입니다. 2023년에 회사는 $7.02B의 수익을 올렸으며 이는 2022년의 $6.60B 대비 증가입니다. 수익은 상품이나 서비스를 판매하여 얻은 총 수입을 의미합니다. 수익과는 달리 비용이 차감되지 않습니다.
China National Medicines Corporation Ltd.의 수익 기록 (2000 ~ 2026)
매년 말 매출
연도 매출 변화
2026 (TTM) $7.76B 11.97%
2024 $6.93B -1.26%
2023 $7.02B 6.44%
2022 $6.60B -9.78%
2021 $7.31B 18.28%
2020 $6.18B -3.59%
2019 $6.41B 13.84%
2018 $5.63B 0.99%
2017 $5.58B 11.87%
2016 $4.99B 168.02%
2015 $1.86B -0.15%
2014 $1.86B 12.08%
2013 $1.66B 20.63%
2012 $1.38B 23.34%
2011 $1.12B 24.59%
2010 $896.61M 17.84%
2009 $760.87M 18.39%
2008 $642.69M 31.31%
2007 $489.45M 36.11%
2006 $359.59M 24.36%
2005 $289.14M 32.86%
2004 $217.63M 22.35%
2003 $177.87M 20.30%
2002 $147.86M 0.22%
2001 $147.54M 11.05%
2000 $132.86M 0.00%
유사 기업 또는 경쟁사의 매출
회사 매출 매출 차이 국가
$410.98B 5,194.83%
US
- -
US
$254.25B 3,175.56%
US
- -
US
$7.64B -1.55%
AU